Anti-lymphotoxin-beta receptor antibodies, pharmaceutical composition containing the same and pharmaceutical application thereof

A composition and antibody technology, applied in the field of lymphotoxin heteropolymer complexes, anti-lymphotoxin-β receptor antibodies to enhance the cytotoxicity of tumor cells, and anti-lymphotoxin-β receptor antibodies, which can solve ligands problems such as inability to combine

Inactive Publication Date: 2007-01-24
BIOGEN MA INC
View PDF19 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Importantly, LT-α1 / β2 ligands do not bind TNF-R with any appreciable affinity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-lymphotoxin-beta receptor antibodies, pharmaceutical composition containing the same and pharmaceutical application thereof
  • Anti-lymphotoxin-beta receptor antibodies, pharmaceutical composition containing the same and pharmaceutical application thereof
  • Anti-lymphotoxin-beta receptor antibodies, pharmaceutical composition containing the same and pharmaceutical application thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0159] Preparation of supernatants of baculovirus-infected insect cells containing LT-α / β forms

[0160] Recombinant baculoviruses encoding either full-length LT-[alpha] or a secreted form of LT-[beta] were prepared as described (Crowe et al., Science, 264, PP707-710 (1994)). Take 2×10 5 Density of cells / ml High five insect cells (Invitrogen, San Diego, CA) were inoculated into 7.2 liters of serum-free SF900-II (Gibco) medium. After 48 hours the culture reached 1.8 × 10 6 Cells / ml, use 150ml (3×10 8 PFU / ml) LT-β and 300ml LT-α baculovirus stock solution infection. Cultures were harvested after 2 days and cellular debris removed by centrifugation. EDTA and PMSF (final concentrations of 1 mM EDTA and 150 [mu]M PMSF) were added and the clarified supernatant was concentrated 10-fold by ultrafiltration using a SIYM10 (Amicon) spiral column. The concentrate was divided into 6 aliquots of 120 ml each and aliquots were stored at -70°C until further purification.

example 2

[0162] Preparation of soluble LT-β receptors as immunoglobulin Fc chimeras

[0163] The extracellular domain of LT-β-R up to the transmembrane region was amplified from cDNA clones by PCR using primers that incorporated NotI and SalI restriction enzyme sites at their 5' and 3' ends, respectively (Browning et al., J. . Immunol., 154, PP. 33-46 (1995)). The amplified product was cleaved with NotI and SalI, purified, and ligated together with the SalI-NotI fragment encoding the Fc fragment of human IgG1 into the vector pMD901 linearized by NotI. The resulting vectors contained the dihydrofolate reductase gene and the LT-β-R-Fc chimera driven by different promoters. The vector was introduced into CHO dhfr- cells by electroporation, and methotrexate-resistant clones were isolated by standard methods. LT-β-R-Fc was secreted into the culture medium, and cell lines producing large amounts of the chimeric protein were selected by ELISA assay. Grow high-producing cell lines to larger...

example 3

[0165] Affinity chromatography of LT-α1 / β2 with TNF-R and LT-β-R

[0166] To prepare receptor for affinity purification of the LT form of receptor, LT-β-R-Fc (as described in Example 2 herein) and TNF-R A purified preparation of p60-Fc (Crowe et al., Science, 264, pp. 707-10 (1994)) was immobilized on CNBr-Sepharose (Pharmacia). The resin was subjected to one round of elution prior to use. A portion (120 ml) of the SIY10 concentrate was passed through two consecutive LT-α and LT-α2 / β1 bound p60TNF-R-Fc columns. The flow-through material containing LT-α1 / β2 and LT-β was passed through a LT-β-R-Fc column. Wash the column with 5 column volumes of PBS, PBS containing 0.5M NaCl, and PBS, respectively, and then use 25 mM sodium phosphate, 100 mM NaCl, pH 3.5 to elute LT-α and LT-α2 / β1 complexes. The eluted fractions were immediately eluted with 1 / 20 volume of 0.5M sodium phosphate, pH 8.6, and kept on ice. Protein-containing fractions were identified by absorbance at 280 nm, pea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

This invention relates to compositions and methods useful for activating LT- beta receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin- alpha and multiple subunits of lymphotoxin- beta , which induce cytotoxic effects on tumor cells in the presence of lymphotoxin- beta receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin- beta receptor which act as lymphotoxin- beta receptor activating agents alone or in combination with other lymphotoxin- beta receptor activating agents either in the presence or absence of lymphotoxin- alpha / beta complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin- beta receptor antibodies either alone or in the presence of other lymphotoxin- beta receptor activating agents to potentiate tumor cell cytotoxicity.

Description

[0001] This application is a divisional application of the application dated January 26, 1996, application number 200410007058.5, and invention titled "Application of Anti-LT-β-R Antibody in Preparation of Pharmaceutical Composition". technical field [0002] The present invention relates to compositions and methods for activating lymphotoxin-beta receptor signaling, whereby the activated receptor signaling elicits potent anti-proliferative effects on tumor cells. More specifically, the present invention relates to a lymphotoxin heteromeric complex formed between multiple subunits of lymphotoxin-alpha and lymphotoxin-beta, which, in the presence of a lymphotoxin-beta receptor activator, The complex can induce cytotoxic effects on tumor cells. The present invention also relates to antibodies against lymphotoxin-beta receptors acting alone or in combination with other lymphotoxin-beta receptor activators in the presence or absence of lymphotoxin-alpha / beta ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/46A61K39/395A61P35/00A61K38/00G01N33/566A61K38/19A61K38/21C07K14/525C07K14/715C12N5/20C12P21/08G01N33/00
CPCA61K38/191A61K39/395C07K16/2866C07K2319/00A61K39/39541C07K14/715A61K2039/505C07K14/525C07K2317/73C07K2319/30C07K2317/74A61P35/00A61K2300/00A61K38/19
Inventor J·L·布朗宁W·迈耶C·D·本杰明
Owner BIOGEN MA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products